Glimed MF 2mg/500mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake by tissues. The synergistic action of these agents helps achieve better glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Glimed MF is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to Glimepiride’s insulinotropic effect. Regular monitoring of blood glucose levels, renal function, and periodic assessment of glycemic control are recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability to optimize efficacy and minimize adverse effects.